Lenalidomida Grindeks

Lenalidomide, the active ingredient in Lenalidomida Grindeks, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It treats certain blood cancers such as multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomida Grindeks as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is employed in hematologic malignancies where modulation of the immune system and inhibition of angiogenesis are therapeutic goals. - Multiple myeloma: improves progression‑free survival and overall response when used in combination therapy. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may improve blood counts. - Mantle cell lymphoma: contributes to disease control as part of combination regimens.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may affect hydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: increased risk of blood clots. - Severe neutropenia: markedly reduced neutrophil counts, raising infection risk. - Secondary primary malignancies: rare emergence of new cancers.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy: contraindicated; teratogenic (Category X) and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: adjust dosing and monitor renal function closely. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original container.

Lenalidomide can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immune modulation.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase lenalidomide plasma levels. - Antifungal azoles (e.g., ketoconazole): can elevate exposure and require monitoring. - NSAIDs: may augment the risk of thrombotic events when combined with lenalidomide.